Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments
Newleos Therapeutics, a Boston-based biotech startup, has emerged with a $93.5 million Series A financing235.
The company was co-founded by Longwood Fund and experienced CNS drug development leaders23.
Newleos has in-licensed multiple clinical-stage programs from Roche, including oral small molecules targeting novel mechanisms for neuropsychiatric disorders25.
The lead program, NTX-1955, is a first-in-class GABAA-γ1 selective positive allosteric modulator aimed at treating generalized anxiety disorder25.
Other pipeline candidates target social anxiety disorder, substance use disorders, and cognitive impairment35.
The Series A funding was led by Goldman Sachs Alternatives, with participation from Novo Holdings, Longwood Fund, DCVC Bio, and Arkin Bio Capital23.
Newleos plans to use the funds to conduct proof-of-concept clinical trials across its programs23.
The company aims to address high unmet needs in mental health conditions affecting over 60 million individuals in the US38.
Newleos currently has 10 employees and plans to expand to up to 20 team members by the end of 20253.
The startup's approach focuses on developing safer and more effective treatments for neuropsychiatric disorders without the side effects associated with current medications35.
Sources:
2. https://www.fiercebiotech.com/biotech/longwood-fund-unveils-neuro-biotech-93m-assets-licensed-roche
3. https://www.bizjournals.com/boston/news/2025/02/13/newleos-therapeutics-launches-longwood-fund.html
5. https://www.biospace.com/business/newleos-raises-93-5m-to-advance-neuropsychiatric-cast-offs-from-roche
8. https://www.stocktitan.net/news/GS/newleos-therapeutics-debuts-with-93-5-million-oversubscribed-series-871n6h9rcoz8.html